NOT FOR RELEASE, PUBLICATION OR
DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION.
FOR IMMEDIATE RELEASE
21 JUNE 2024
Oxford Nanopore Technologies plc ("Oxford
Nanopore" or "the Company")
Issue of Equity and Total Voting
Rights
The Company
today announces in respect of the period from 1 June to 21 June 2024, the issue of
11,097,812 ordinary shares of £0.0001 each, following:
·
the issue of 11,041,901
ordinary shares to satisfy the vesting of awards under Oxford
Nanopore's Long Term Incentive Plan; and
·
the exercise of
options granted under the Company's share option plans and issuance
of shares under certain of the Company's remuneration schemes and
such ordinary shares were admitted to the Official List of the
Financial Conduct Authority ("FCA") and to trading on the London Stock Exchange's
main market for listed securities under the Company's block listing
facility. Following this issue, the Company has the ability to
admit a further 19,436,423 ordinary shares under its block listing
facility.
In
accordance with the FCA's Disclosure Guidance and Transparency Rule
5.6.1, the Company announces that as at 21 June 2024, the Company's
issued share capital consisted of 873,921,325 ordinary shares, one
class A limited anti-takeover ("LAT") share of £1.00, one class B LAT share of
£1.00 and one class C LAT share of £1.00 and the Company will not
hold any shares in treasury. Only the ordinary shares are voting
shares and each such ordinary share carries one vote per ordinary
share. Accordingly, the total number of voting rights in the
Company as at 21 June 2024 is 873,921,325. This figure may be used
by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
For further
information, please contact:
Oxford Nanopore Technologies
plc
Investors:
ir@nanoporetech.com
Media:
media@nanoporetech.com
Teneo
(communications adviser to the Company)
Tom Murray,
Olivia Peters
+44 (0) 20
7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies
plc:
Oxford Nanopore Technologies' goal is to
bring the widest benefits to society through enabling the analysis
of anything, by anyone, anywhere. The company has developed a new
generation of nanopore-based sensing technology for real-time,
high-performance, accessible and scalable analysis of DNA and RNA.
The technology is used in more than 120 countries to understand the
biology of humans and diseases such as cancer, plants, animals,
bacteria,
viruses and whole environments. Oxford
Nanopore Technologies products are intended for molecular biology
applications and are not intended for diagnostic
purposes.
www.nanoporetech.com
Forward-looking
statements
This announcement contains certain
forward-looking statements. For example, statements regarding
expected revenue growth and profit margins are forward-looking
statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar
expressions of a future or forward-looking nature should also be
considered forward-looking statements. Forward-looking statements
address our expected future business and financial performance and
financial condition, and by definition address matters that are, to
different degrees, uncertain. Our results could be affected by
macroeconomic conditions, the COVID-19 pandemic, delays in our
receipt of components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products
or accelerated adoption of pathogen surveillance. These or other
uncertainties may cause our actual future results to be materially
different than those expressed in our forward-looking
statements.